For research use only. Not for therapeutic Use.
SL0101 is a highly specific RSK inhibitor. SL0101 showed improved in vitro biological stability while maintaining specificity for RSK. These results should facilitate the development of RSK inhibitors derived from SL0101 as anticancer agents.
| Catalog Number | R004415 |
| CAS Number | 77307-50-7 |
| Synonyms | 3-[(3,4-Di-O-acetyl-6-deoxy-α-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Kaempferol; 3’’,4’’-Di-O-acetylafzelin; |
| Molecular Formula | C₂₅H₂₄O₁₂ |
| Purity | ≥95% |
| Target | Ribosomal S6 Kinase (RSK) |
| Solubility | Limited solubility |
| Storage | Store at -20°C |
| InChI | InChI=1S/C25H24O12/c1-10-21(34-11(2)26)24(35-12(3)27)20(32)25(33-10)37-23-19(31)18-16(30)8-15(29)9-17(18)36-22(23)13-4-6-14(28)7-5-13/h4-10,20-21,24-25,28-30,32H,1-3H3/t10-,20+,21-,24-,25-/m0/s1 |
| InChIKey | SXOZSDJHGMAEGZ-IGKKHSBFSA-N |
| SMILES | CC1C(C(C(C(O1)OC2=C(OC3=CC(=CC(=C3C2=O)O)O)C4=CC=C(C=C4)O)O)OC(=O)C)OC(=O)C |
| Reference | </br>1:Stereoselective Synthesis and Evaluation of C6″-Substituted 5a-Carbasugar Analogues of SL0101 as Inhibitors of RSK1/2. Li M, Li Y, Ludwik KA, Sandusky ZM, Lannigan DA, O/’Doherty GA.Org Lett. 2017 May 5;19(9):2410-2413. doi: 10.1021/acs.orglett.7b00945. Epub 2017 Apr 25. PMID: 28441024 </br>2:Two widely used RSK inhibitors, BI-D1870 and SL0101, alter mTORC1 signaling in a RSK-independent manner. Roffé M, Lupinacci FC, Soares LC, Hajj GN, Martins VR.Cell Signal. 2015 Aug;27(8):1630-42. doi: 10.1016/j.cellsig.2015.04.004. Epub 2015 Apr 16. PMID: 25889895 </br>3:Synthesis and Structure-Activity Relationship Study of 5a-Carbasugar Analogues of SL0101. Li M, Li Y, Mrozowski RM, Sandusky ZM, Shan M, Song X, Wu B, Zhang Q, Lannigan DA, O/’Doherty GA.ACS Med Chem Lett. 2014 Nov 26;6(1):95-9. doi: 10.1021/ml5004525. eCollection 2015 Jan 8. PMID: 25589938 Free PMC Article</br>4:De novo synthesis and biological evaluation of C6″-substituted C4″-amide analogues of SL0101. Mrozowski RM, Sandusky ZM, Vemula R, Wu B, Zhang Q, Lannigan DA, O/’Doherty GA.Org Lett. 2014 Nov 21;16(22):5996-9. doi: 10.1021/ol503012k. Epub 2014 Nov 5. PMID: 25372628 Free PMC Article</br>5:Improving the affinity of SL0101 for RSK using structure-based design. Mrozowski RM, Vemula R, Wu B, Zhang Q, Schroeder BR, Hilinski MK, Clark DE, Hecht SM, O/’Doherty GA, Lannigan DA.ACS Med Chem Lett. 2012 Feb 14;4(2):175-179. Epub 2012 Dec 26. PMID: 23519677 Free PMC Article</br>6:Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 Å crystal structure of the N-terminal domain of RSK2 with bound inhibitor. Utepbergenov D, Derewenda U, Olekhnovich N, Szukalska G, Banerjee B, Hilinski MK, Lannigan DA, Stukenberg PT, Derewenda ZS.Biochemistry. 2012 Aug 21;51(33):6499-510. doi: 10.1021/bi300620c. Epub 2012 Aug 6. PMID: 22846040 Free PMC Article</br>7:Analogs of the RSK inhibitor SL0101: optimization of in vitro biological stability. Hilinski MK, Mrozowski RM, Clark DE, Lannigan DA.Bioorg Med Chem Lett. 2012 May 1;22(9):3244-7. doi: 10.1016/j.bmcl.2012.03.033. Epub 2012 Mar 13. PMID: 22464132 Free PMC Article</br>8:Synthesis of SL0101 carbasugar analogues: carbasugars via Pd-catalyzed cyclitolization and post-cyclitolization transformations. Shan M, O/’Doherty GA.Org Lett. 2010 Jul 2;12(13):2986-9. doi: 10.1021/ol101009q. PMID: 20518547 Free PMC Article</br>9:Structural basis for the activity of the RSK-specific inhibitor, SL0101. Smith JA, Maloney DJ, Hecht SM, Lannigan DA.Bioorg Med Chem. 2007 Jul 15;15(14):5018-34. Epub 2007 Apr 2. PMID: 17512736 </br>10:De novo asymmetric syntheses of SL0101 and its analogues via a palladium-catalyzed glycosylation. Shan M, O/’Doherty GA.Org Lett. 2006 Oct 26;8(22):5149-52. PMID: 17048865 Free PMC Article |
